drugset
drugset / Trial / NCT07096128

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

NCT07096128 ↗

Phase 1 Recruiting 36 enrolled Jinming Zhang Sinotau Pharmaceutical Group · collab
NaSingle-groupOpen-labelTreatment

Summary

This was a multicenter, open-label, phase I study to evaluate the safety, tolerability, radiation dosimetry and efficacy of \[177Lu\] Lu-PSMA-XT injection in patients with metastatic prostate cancer .

Timeline

Start
2024-08-20
Primary completion
2026-05-31
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject [177Lu]Lu-PSMA-XT Other / unclassified — —

Indications

castration-resistant prostate carcinoma